Business
NorthStrive Biosciences Announces Completion of Phase I Strategic Review for EL-22 Targeting Muscle Loss Associated with GLP-1 Weight Loss Drugs and Age-Related Sarcopenia
NEWPORT BEACH, Calif., May 22, 2025 (GLOBE NEWSWIRE) -- Northstrive Biosciences Inc. (“Northstrive”), a subsidiary of PMGC Holdings Inc. (NASDAQ: ELAB) (the “Company,” “PMGC,” “we,” or “our”), today announced the completion of a Phase I strategic research and literature synthesis for EL-22 (formerly BLS-M22), its first-in-class oral myostatin-engineered probiotic. The analysis, conducted in collaboration with Yuva Biosciences and supported by AI-based scientific review technology from Yuva Biosc
About this update from Pmgc Holdings Inc.
[{"type":"image","alt":"PMGC Holdings Inc.","displaySize":"","headline":null,"caption":"PMGC Holdings Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":243,"url":"https://media.zenfs.com/en/globenewswire.com/546741842ddd656c130df2366fbdd9a7"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/FeIekmuAEqql.btYh_OPxw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTM0MDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/546741842ddd656c130df2366fbdd9a7","width":300,"height":243}},"lazy":false},{"type":"text","content":"NEWPORT BEACH, Calif., May 22, 2025 (GLOBE NEWSWIRE) -- Northstrive Biosciences Inc. (“Northstrive”), a subsidiary of PMGC Holdings Inc. (NASDAQ: ELAB) (the “Company,” “PMGC,” “we,” or “our”), today announced the completion of a Phase I strategic research and literature synthesis for EL-22 (formerly BLS-M22), its first-in-class oral myostatin-engineered probiotic. The analysis, conducted in collaboration with Yuva Biosciences and supported by AI-based scientific review technology from Yuva Biosciences’ MitoNova™, provided valuable insights into EL-22’s proposed mechanism of action and will help guide further exploration into its potential to address critical unmet needs in muscle-wasting conditions, including GLP-1-associated atrophy and age-related sarcopenia.","length":776,"tagName":"p"},{"type":"text","content":"EL-22 is leveraging a myostatin-engineered probiotic approach to address obesity’s pressing issue of preserving muscle while on weight loss treatments, including GLP-1 receptor agonists. The oral biologic is designed to induce a targeted immune response against myostatin, a key negative regulator of muscle growth. Unlike traditional injectable antibodies, EL-22 leverages genetically engineered Lactobacillus casei to stimulate the gut immune system, offering a convenient, patient-friendly oral delivery method with potential safety and efficacy advantages.","length":560,"tagName":"p"},{"type":"text","content":"Key Highlights from the Report:","length":31,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Strong Preclinical Rationale: Synthesized findings from published peer-reviewed literature, highlight noteworthy effects of EL-22 in mdx mice on antibody production, serum CK, body weight, motor function, and muscle histology.","length":226,"tagName":"p"}]},{"val":[{"type":"t...